DAMAE Medical

What DAMAE Medical does

DAMAE Medical is a Paris-based medical device company founded in September 2014 by Anaïs Barut (CEO), David Siret (CTO), and Pr. Arnaud Dubois (CSO) to commercialize Line-field Confocal Optical Coherence Tomography (LC-OCT) technology for non-invasive skin cancer detection. The company's flagship product, deepLive™, is a medical imaging device that pairs penetration depth with cellular resolution, enabling dermatologists to switch between histology-like vertical and confocal-like horizontal imaging modes and record 3D volumetric stacks of skin tissue in situ. The system integrates quantitative skin analysis algorithms including 3D segmentation of skin surfaces, dermo-epidermal junctions, keratinocyte density distributions, and collagen fiber architecture, with AI-assisted diagnosis for basal cell carcinoma demonstrated in published clinical studies. The device received CE Mark Class IIA under EU MDR 2017/745 in March 2023 and FDA 510(k) clearance in March 2025.

The company addresses three persistent gaps in dermatology diagnostics: the high rate (60%) of biopsies yielding benign diagnoses, the ~20% of skin cancers missed at early stage by dermoscopy when performed by less experienced examiners, and the need for accurate pre-surgical margin guidance. DAMAE Medical sells deepLive systems through direct sales to dermatology clinics, hospitals, and academic medical centers across 10+ countries in Europe, Japan, Australia, and the United States, with revenue generated from both hardware sales and recurring software/cloud-based imaging services. Approximately twenty collaborators work from the company's Paris headquarters, which houses R&D, production, and a scalable manufacturing strategy implemented with industrial partners since 2021. The company is building clinical evidence through 170+ peer-reviewed publications and the ECOBASO randomized health-economic study (launched April 2024) designed to validate health-economic impact on BCC management.

DAMAE Medical has raised approximately €22.4 million in disclosed capital, including a €2 million seed round in 2017, a €2.4 million EU Horizon 2020 grant in 2019, a €5 million Series A in February 2022 led by BNP Paribas Développement, and a €15 million Series B in November 2025 led by Creadev with the Mulliez family investment arm contributing over €10 million. The Series B funding is intended to support the company's growth toward becoming a sector leader in non-invasive skin cancer diagnostics.

Name

DAMAE Medical

Legal name

Damae Medical

Website

https://damae-medical.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

DAMAE Medical is a Paris-based medical device company founded in 2014 that develops deepLive™, an LC-OCT imaging system enabling non-invasive 3D skin cancer detection with cellular resolution, sold to dermatology clinics and hospitals across 10+ countries in Europe, Asia-Pacific, and the United States.

Ownership category

akta.pro rank

Product category

Dermatological Diagnostic Imaging Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Optical Instruments & Lenses (3827)

akta.pro industry

PRIMARYHLAGAIAE

Microscopy, Imaging & Flow Cytometry Instruments

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Laboratory Equipment, Instruments & Consumables

SECONDARYHLACANAG

SaMD – Imaging & Signal Analysis (AI/ML)

Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

• Medical imaging devices
• Skin cancer diagnostics
• Optical coherence tomography
• Dermatology imaging systems
• Non-invasive skin analysis

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Medical device sales: Sale of deepLive™ medical imaging systems to healthcare institutions, dermatology clinics, and hospitals for skin cancer screening and diagnosis
2. Clinical imaging services and software: Computer-aided software for OCTAV image interpretation, telepathology, and patient services based on cloud platform

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

DAMAE Medical develops and manufactures deepLive™, a medical imaging device based on proprietary LC-OCT (Line-field Confocal Optical Coherence Tomography) technology. The device provides 3D cellular-resolution imaging of skin tissue in vivo, enabling non-invasive dermatological examination without biopsy. It is sold to healthcare institutions, dermatology clinics, and hospitals for screening and management of skin cancers including basal cell carcinoma and melanoma.

Product overview

Damae Medical offers a single unified product, deepLive™, which is a medical imaging system based on proprietary LC-OCT (Line-field Confocal Optical Coherence Tomography) technology. The device provides real-time 3D imaging of skin tissue with cellular resolution, allowing dermatologists to examine skin structures non-invasively without requiring biopsy. The product received CE Mark Class IIA (March 2023) and FDA 510(k) clearance (March 2025), and is deployed across Europe, Japan, Australia, and the United States.

Differentiator

Problem solved

Functional benefit

Brands

• deepLive™: Medical device imaging system using LC-OCT technology for skin cancer screening and analysis. Provides 3D imaging with cellular resolution for non-invasive examination of skin conditions.

Products and services

• deepLive™ medical imaging device Medical imaging device based on proprietary LC-OCT (Line-field Confocal Optical Coherence Tomography) technology that provides 3D cellular-resolution imaging of skin tissue in vivo. Enables non-invasive examination of skin conditions without biopsy, adapted to imaging of multiple skin conditions for efficient and reassuring patient management. Sold to dermatology clinics, hospitals, and academic medical centers for skin cancer screening and management of basal cell carcinoma, melanoma, and non-melanoma skin cancers.

Quantifiable outcome

• 60% of biopsies result in benign diagnoses, indicating significant potential for non-invasive alternatives
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Caliber Imaging & Diagnostics: Maker of VivaScope reflectance confocal microscopy systems for non-invasive skin imaging and dermatology diagnosis. Directly comparable to DAMAE Medical as both companies sell cellular-resolution imaging devices targeting dermatologists for skin cancer and lesion management.
• Michelson Diagnostics: Developer of the Vivosight multi-beam OCT skin imaging system used in dermatology clinics for non-invasive skin lesion assessment. Comparable to DAMAE Medical's deepLive™ as both deploy optical coherence tomography-based imaging in dermatology practices.

Broad incumbents

• FotoFinder Systems: Established German manufacturer of digital dermoscopy, total body photography and AI-assisted skin imaging systems widely deployed in dermatology practices. Comparable as a dermatology imaging hardware vendor serving the same clinical customers as DAMAE Medical, though with a broader imaging portfolio.
• Canfield Scientific: Major supplier of dermatology imaging systems, including VECTRA 3D and DermaGraphix, used by dermatologists and plastic surgeons. Comparable to DAMAE Medical as a medical imaging vendor in dermatology with established US distribution that DAMAE Medical is entering via its 2025 FDA clearance.
• 3Gen / Dermlite: Leading manufacturer of handheld dermatoscopes widely used in dermatology practices. Comparable to DAMAE Medical as a primary dermatology examination device vendor, although Dermlite's products are low-cost 2D optical instruments versus deepLive™'s 3D cellular imaging system.
• Heidelberg Engineering: Developer of SPECTRALIS OCT and other ophthalmic/spectral imaging platforms used in medical imaging. Comparable to DAMAE Medical as a high-end optical coherence imaging vendor with clinical evidence-based marketing, though primarily focused on ophthalmology.
• Agfa HealthCare: Enterprise imaging and radiology IT vendor with dermatology and AI imaging solutions deployed in hospitals. Comparable to DAMAE Medical as a vendor enabling dermatology imaging workflows in hospitals, though operating at a broader enterprise imaging portfolio level.

Emerging players

• Skin Analytics: UK-based company offering AI-driven dermatology diagnostic software (DERM) for skin cancer detection. Comparable to DAMAE Medical's AI-assisted LC-OCT diagnostics as a technology-enabled alternative for skin cancer triage, though using smartphone/2D image input rather than 3D cellular imaging.
• MetaOptima Technology: Developer of DermEngine, an intelligent dermatology imaging and AI platform with teledermatology workflows used by skin clinics. Comparable to DAMAE Medical at the software/AI diagnostic layer of skin imaging, though focused on dermoscopy-based workflows rather than LC-OCT.

Regional players

• Optopol Technology: Polish manufacturer of OCT imaging devices used in ophthalmology and dermatology applications across Central/Eastern Europe. Comparable to DAMAE Medical as an OCT-system vendor targeting dermatology imaging use cases, though with a regional rather than global commercial focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/damae_medical

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds8 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DAMAE Medical